In recent months, diabetes stocks have retreated sharply, partly due to the increased popularity of the weight-loss drug Semaglutide. Some have contended that Semaglutide will greatly reduce the number of people suffering from diabetes in America. But, I believe that this thesis is misguided for three reasons. First, the drug only reduces patients’ weight by 15%-20% . Even after losing that amount of weight, a high percentage of Americans will still be meaningful overweight and obese, rendering them vulnerable to diabetes. Secondly, the drug is administered through an injection once a week and loses its effectiveness after patients stop taking it. And the drug can result in some significant, negative side effects. This increases the chances that patients will stop taking it after a relatively short amount of time. Given these points, I believe that investors should buy these three diabetes stocks while they are in a downturn. DexCom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com On July 27, DexCom (NASDAQ: DXCM ) reported strong second-quarter results , showing that its business is growing rapidly and remains quite profitable.
… the SEC. The institutional investor owned 758,087 shares … 2nd largest position. Beacon Investment Advisory Services Inc. … investors have also bought and sold shares of DXCM. Resources Investment … 116.55. Want More Great Investing Ideas? DexCom (NASDAQ:DXCM …
DexCom (NASDAQ: DXCM ) has outperformed the market over the past 15 years by 22.87% on an annualized basis producing an average annual return of 33.0%. Currently, DexCom has a market capitalization of $36.07 billion. Buying $100 In DXCM: If an … Full story available on Benzinga.com
DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new
COMISAIR study is now the longest prospective real-world CGM study ever conducted, demonstrating significant and continued HbA1c reduction for patients using real-time CGM over seven years.1 New d…
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #COMISAIR--Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there''s one clear-cut stock-split stock that''s notably cheaper than the rest.
As of September 19, S&P 500 healthcare stocks were down 3.2% for the year. Of the 11 sectors, its year to date ( YTD ) performance is the second worst only behind utilities. Over the past decade, the Health Care Select Sector SPDR Fund (NYSEARCA: XLV ) has fared better, averaging an annualized return of 12.23%, putting it in third spot. However, the tech-heavy index has a weighting of 27.13% , or double that of healthcare. The XLV trails the SPDR S&P 500 ETF Trust (NYSEARCA: SPY ) by 48 basis points. Nonetheless, if you can only have one sector ETF in your investment portfolio, it should be healthcare. No other sector has such a profound effect on the overall financial well-being of a country. So let’s explore three healthcare stocks to buy now. BioTechne (TECH) Source: shutterstock.com/Romix Image BioTechne (NASDAQ: TECH ) is a small holding in XLV with just a 0.22% weighting. Barron’s recently produced an article about six healthcare stocks in the S&P 500 with buy ratings, with more than 70% of the analysts covering the stocks.
Gateway Investment Advisers LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 33.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 65,589 shares of the medical device company’s stock after selling 33,527 shares during the quarter. Gateway Investment Advisers LLC’s holdings in DexCom were worth $8,429,000 as of its most recent […]
… during the period. Gateway Investment Advisers LLC’s holdings in … number of other large investors also recently bought and sold … the last quarter. Institutional investors and hedge funds own 93 … $139.55. Want More Great Investing Ideas? DexCom (NASDAQ:DXCM – …